Key result
Vaspin and omentin are novel adipokines whose serum concentrations and tissue expressions fluctuate depending on the presence or severity of systemic or local inflammation.
Why the study?
Excess white adipose tissue drives chronic inflammation via adipokines, and the clinical usefulness of novel adipokines vaspin and omentin as biomarkers in inflammatory diseases required review.
Vaspin and omentin are novel adipokines that modulate inflammation and insulin sensitivity, showing promise as future biomarkers for chronic inflammatory and metabolic diseases.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for vaspin and omentin as biomarkers; prospective validation required before clinical use.
Obesity is a disease of epidemic proportions in many countries around the world. White adipose tissue is an active endocrine organ; therefore, its excess results in chronic and systemic inflammation. This inflammation is caused and maintained mostly by adipokines secreted by adipose tissue cells, mainly adipocytes and macrophages. The relatively newly discovered adipokines comprise vaspin and omentin. Their concentration in the blood, tissues, or bronchial secretion varies depending on the amount of adipose tissue and other accompanying factors, including comorbidities. The aim of this article is to demonstrate the usefulness of omentin and vaspin as biomarkers in inflammatory diseases. The Medline/PubMed database was used to search for information on obesity, inflammation, omentin, vaspin, and adipose tissue. Data from selected scientific studies, both original and review papers, are presented. Vaspin has been found to improve insulin sensitivity mainly in white adipose tissue. Omentin has an anti-inflammatory effect and, like vaspin, sensitizes tissues to insulin. The serum concentration and tissue expression of both adipokines are different in different inflammatory diseases. This review aims to present the biological functions of vaspin and omentin in the body and to indicate the possible use of these adipokines as disease markers in the future.
No takes yet. Share an insight, caveat, or question.
Radzik-Zając et al. (2022) conducted a review in chronic inflammatory diseases. Vaspin and omentin was evaluated. Vaspin and omentin are novel adipokines whose serum concentrations and tissue expressions fluctuate depending on the presence or severity of systemic or local inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: